Nippon India Pharma Fund-Growth
The fund is rated 0 stars. Balance between returns and downside risk provided limited support. Investment selection within each asset type and investment selection within each industry were the main limitations and did not provide enough support for a higher rating. Higher annual fee of 1.84% and above-average fund size of Rs 9,479.08 crore were minor drawbacks.
This fund has a bad track record with Asset Selection/Timing, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 9479.076 AUM and a 1.84 expense ratio. Considering all these factors, we have rated this fund as 0.0 star.
எங்கள் score நீண்டகால performance, risk மற்றும் consistency-ஐ மதிப்பிடுகிறது — past returns மட்டும் அல்ல.
Returns
8 Oct 2026 நிலவரப்படி
Risk ratios
30 Sep 2026 நிலவரப்படி
Portfolio
31 Aug 2026 நிலவரப்படி
Market-cap பிரிவு
துறை ஒதுக்கீடு
Holdings (37)
| Holding | Fund-இன் % | மதிப்பு | பங்குகள் |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 12.37% | ₹1,172.29 Cr | 59,06,349 |
| Divi's Laboratories Ltd. | 7.00% | ₹663.4 Cr | 7,00,754 |
| Lupin Ltd. | 6.43% | ₹609.25 Cr | 27,83,991 |
| Cipla Ltd. | 6.09% | ₹577.08 Cr | 40,95,054 |
| Apollo Hospitals Enterprise Ltd. | 5.15% | ₹488.35 Cr | 5,48,795 |
| Dr. Reddy's Laboratories Ltd. | 4.93% | ₹467.5 Cr | 40,49,746 |
| Mankind Pharma Ltd. | 4.09% | ₹387.93 Cr | 16,03,562 |
| Sai Life Sciences Ltd. | 3.94% | ₹373.06 Cr | 25,55,745 |
| Ajanta Pharma Ltd. | 3.47% | ₹329.18 Cr | 9,13,918 |
| Glaxosmithkline Pharmaceuticals Ltd. | 3.31% | ₹314 Cr | 10,29,460 |
Fund விவரங்கள்
Long term capital growth. Investment in equity and equity related Securities of pharma & other associated companies.
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Exit load of 1% if redeemed within 1 month.